LBCA Executive Director, Laurie Hutcheson, recently interviewed Dr. Julia Foldi about the results of her latest study, Personalized Circulating Tumor DNA Testing for Detection of Progression and Treatment Response Monitoring in Patients With Metastatic Invasive Lobular Carcinoma of the Breast, which was presented at the American Society of Clinical Oncology (ASCO) in June. 

Dr. Foldi shares her interest in studying lobular breast cancer, and aim to develop novel methods to evaluate patients with ILC and follow their treatment response, due to the challenges in diagnosis and treatment that ILC presents. She shares the significance of this study’s results, which show that serial ctDNA testing in patients with mILC is feasible and may enable personalized surveillance and real-time therapeutic monitoring.  

Dr. Foldi’s research poster from ASCO is below; to see her presentation slides click here.